{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:02:28Z","timestamp":1794988948910,"version":"4.9.1"},"reference-count":22,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The revised 4th edition of the World Health Organization (WHO4R) classification lists myelodysplastic syndromes with ring sideroblasts (MDS-RS) as a separate entity with single lineage (MDS-RS-SLD) or multilineage (MDS-RS-MLD) dysplasia. The more recent International Consensus Classification (ICC) distinguishes between MDS with SF3B1 mutation (MDS-SF3B1) and MDS-RS without SF3B1 mutation; the latter is instead included under the category of MDS not otherwise specified. The current study includes 170 Mayo Clinic patients with WHO4R-defined MDS-RS, including MDS-RS-SLD (N=83) and MDS-RSMLD (N=87); a subset of 145 patients were also evaluable for the presence of SF3B1 and other mutations, including 126 with (87%) and 19 (13%) without SF3B1 mutation. Median overall survival for all 170 patients was 6.6 years with 5- and 10-year survival rates of 59% and 25%, respectively. A significant difference in overall survival was apparent between MDS-RS-MLD and MDS-RS-SLD (P&lt;0.01) but not between MDS-RS with and without SF3B1 mutation (P=0.36). Multivariable analysis confirmed the independent prognostic contribution of MLD (hazard ratio=1.8, 95% confidence interval: 1.1-2.8; P=0.01) and also identified age (P&lt;0.01), transfusion need at diagnosis (P&lt;0.01), and abnormal karyotype (P&lt;0.01), as additional risk factors; the impact from SF3B1 or other mutations was not significant. Leukemia-free survival was independently affected by abnormal karyotype (P&lt;0.01), RUNX1 (P=0.02) and IDH1 (P=0.01) mutations, but not by MLD or SF3B1 mutation. Exclusion of patients not meeting ICC-criteria for MDS-SF3B1 did not change the observations on overall survival. MLD-based, as opposed to SF3B1 mutation-based, disease classification for MDS-RS might be prognostically more relevant.<\/jats:p>","DOI":"10.3324\/haematol.2023.284719","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:11:02Z","timestamp":1709777462000},"page":"2525-2532","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic impact of &lt;i&gt;SF3B1&lt;\/i&gt; mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases"],"prefix":"10.3324","volume":"109","author":[{"given":"Faiqa","family":"Farrukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maymona","family":"Abdelmagid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"64385","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51(2):189-199.","DOI":"10.1111\/j.1365-2141.1982.tb08475.x"},{"key":"64386","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"64387","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"64388","doi-asserted-by":"crossref","unstructured":"Mufti GJ, Bennett JM, Goasguen J. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008; 93(11):1712-1717.","DOI":"10.3324\/haematol.13405"},{"key":"64389","doi-asserted-by":"crossref","unstructured":"Mangaonkar AA, Lasho TL, Finke CM. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer J. 2018; 8(2):18.","DOI":"10.1038\/s41408-018-0051-1"},{"key":"64390","doi-asserted-by":"crossref","unstructured":"Buckstein R, Chodirker L, Mozessohn L. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. Leuk Lymphoma. 2022; 63(13):3165-3174.","DOI":"10.1080\/10428194.2022.2109154"},{"key":"64391","doi-asserted-by":"crossref","unstructured":"Migdady Y, Barnard J, Al Ali N. Clinical outcomes with ring sideroblasts and SF3B1 mutations in myelodysplastic syndromes: MDS clinical research consortium analysis. Clin Lymphoma Myeloma Leuk. 2018; 18(8):528-532.","DOI":"10.1016\/j.clml.2018.05.016"},{"key":"64392","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Thiele J, Arber DA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-951.","DOI":"10.1182\/blood-2009-03-209262"},{"key":"64393","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"64394","doi-asserted-by":"crossref","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020; 136(2):157-170.","DOI":"10.1182\/blood.2020004850"},{"key":"64395","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Hanson CA, Sulai NH. Prognostic irrelevance of ring sideroblast percentage in World Health Organizationdefined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674-5677.","DOI":"10.1182\/blood-2012-03-415356"},{"key":"64396","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Lasho TL, Hodnefield JM. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012; 119(2):569-572.","DOI":"10.1182\/blood-2011-09-377994"},{"key":"64397","doi-asserted-by":"crossref","unstructured":"Mangaonkar AA, Lasho TL, Finke C. SF3B1-mutant myelodysplastic syndrome\/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022; 107(5):1189-1192.","DOI":"10.3324\/haematol.2021.280463"},{"key":"64398","doi-asserted-by":"crossref","unstructured":"Falantes JF, Marquez-Malaver FJ, Carrillo E. SF3B1, RUNX1 and TP53 mutations significantly impact the outcome of patients with lower-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2022; 22(12):e1059-e1066.","DOI":"10.1016\/j.clml.2022.08.012"},{"key":"64399","doi-asserted-by":"crossref","unstructured":"Fenaux P, Platzbecker U, Mufti GJ. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020; 382(2):140-151.","DOI":"10.1056\/NEJMoa1908892"},{"key":"64400","doi-asserted-by":"crossref","unstructured":"Fattizzo B, Marchetti A, Zaninoni A. Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept. Am J Hematol. 2023; 98(11):e345-e348.","DOI":"10.1002\/ajh.27072"},{"key":"64401","doi-asserted-by":"crossref","unstructured":"Platzbecker U, Della Porta MG, Santini V. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesisstimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023; 402(10399):373-385.","DOI":"10.1016\/S0140-6736(23)00874-7"},{"key":"64402","doi-asserted-by":"crossref","unstructured":"Farrukh F, Chetram D, Al-Kali A. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. Am J Hematol. 2022; 97(6):e210-e214.","DOI":"10.1002\/ajh.26533"},{"key":"64403","doi-asserted-by":"crossref","unstructured":"Germing U, Strupp C, Giagounidis A. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012; 36(6):727-734.","DOI":"10.1016\/j.leukres.2012.02.014"},{"key":"64404","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO Classification of tumours of haematopoietic and lymphoid tissues. WHO revised 4th edition. 2017."},{"key":"64405","doi-asserted-by":"crossref","unstructured":"Jafari PA, Sadeghian MH, Miri HH. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: a meta-analysis. Crit Rev Oncol Hematol. 2020; 145:102832.","DOI":"10.1016\/j.critrevonc.2019.102832"},{"key":"64406","doi-asserted-by":"crossref","unstructured":"Cilloni D, Itri F, Bonuomo V, Petiti J. SF3B1 Mutations in hematological malignancies. Cancers (Basel). 2022; 14(19):49.","DOI":"10.3390\/cancers14194927"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284719\/76737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284719\/77344","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11495\/76737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:56Z","timestamp":1794045956000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284719","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}